WORK Medical Secures Exclusive East China Partnership for AI Blood Analysis Technology, Stock Surges

MrRightClick · 2025-12-31T15:28:14+00:00

WORK Medical Technology Group LTD (WOK) partnered with Shanghai Benke Medical Technology to distribute an AI-driven blood analysis tool in East China, targeting major markets. This agreement boosts investor confidence and aims for significant revenue growth.

MrRightClick

2025-12-31 15:28:14

Abstract generation in progress

WORK Medical Technology Group LTD (WOK) unveiled a strategic one-year exclusive distribution agreement with Shanghai Benke Medical Technology on Monday, marking a significant expansion into China’s advanced diagnostic market. The partnership centers on the AI-Automated Blood Cell Morphology Analyzer, a sophisticated fund analyzer tool designed to streamline medical diagnostics across the eastern regions.

The collaboration will focus on commercializing this cutting-edge blood analysis technology throughout East China’s key markets, specifically targeting Jiangsu, Shanghai, and Zhejiang provinces. WORK Medical’s subsidiary, Hunan Saitumofei Medical Treatment Technology, will spearhead the distribution efforts, with an aggressive minimum sales target of RMB 10 million annually.

Market Response and Growth Implications

The market reacted positively to the announcement. WOK stock climbed to $3.26, representing a gain of $0.51 or 18.54 percent on the Nasdaq, signaling investor confidence in the company’s strategic direction. This partnership represents a critical step in accelerating commercialization penetration and reinforcing WORK Medical’s presence within China’s healthcare ecosystem.

The agreement underscores the growing demand for AI-powered diagnostic solutions in China’s medical sector. By leveraging advanced fund analyzer capabilities integrated into their blood cell morphology platform, WORK Medical positions itself to capture significant market share in the eastern region throughout 2026. Industry observers view this exclusive distribution deal as a pivotal move that could strengthen the company’s competitive positioning and drive sustained revenue growth.

Disclaimer: These views and opinions are those of the author and do not necessarily reflect the positions of Nasdaq, Inc.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.